topical ghk-cu purchase Copper Peptide Face Cream with GHK Copper, Barley Seed and Matrix TRIO The Copper Topical (GHK-Cu /

& Carlyle, B

Retatrutide redesigns multi-agonism Approval Outlook Neither CagriSema nor Retatrutide should be treated as FDA-approved therapy in 2026 until regulators say otherwise

Cognitive Decline and Neurodegenerative Conditions Cognitive decline and neurodegenerative conditions show substantial preclinical evidence across multiple pathologies: Stroke models: BPC-157 given during reperfusion counteracted neuronal damage and produced full functional recovery in spatial memory, motor coordination, and balance tests Parkinsons models: MPTP-induced models showed reduced motor symptoms (tremor, rigidity, akinesia), protection of nigrostriatal dopaminergic neurons, and near-complete prevention of mortality Multiple sclerosis models: Cuprizone-induced demyelination resulted in significantly less brain damage and reduced clinical abnormalities when BPC-157 was given in drinking water or intragastrically Traumatic brain injury: Falling weight model studies demonstrated reduced hemorrhage, decreased brain lacerations and edema, and improved early outcomes These diverse models share common mechanisms

Effects of disease states on intra-portal insulin levels and changes in the GH/IGF-I axis High GH and low IGF-I Type 1 diabetes is an autoimmune disease characterized by pancreatic -cell destruction leading to intra-portal hypoinsulinemia